Marty Makary
speaker
939 appearances
6 recordings
5 series
first heard Jan 2026
last heard 13 May
Marty Makary’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 6 in all, peaking in Jan 2026 with 4.
Appearances
to some of the biggest unmet public health needs in our society.
I want to see in the next year or two, and I do believe we're going to achieve this very bold goal, a cure or meaningful treatment for type 1 diabetes, for neurodegenerative disorders,
For certain types of stage 1 and stage 2 cancer, such that a tumor is eliminated without the need for surgery or chemo or radiation, I want to see a universal flu shot so that we don't have to guess each year what the strain is going to be.
A flu shot that would give you immunity for decades against future strains that have yet to mutate.
And I do believe very firmly that we need to get a decision out quickly on these potentially promising treatments for PTSD.
We lose 8,000 veterans a year to suicide.
That's more than the entire Iraq and Afghan wars combined.
The wars are over, but our men and women are still dying.
We owe it to them to get a decision out quickly on some of these potentially promising treatments for PTSD.
People have gone overseas or used some of these products in the black market.
We can regulate this so it can be given safely to Americans who may not have the wealth or access to be able to get them overseas.
Well, my area of clinical medicine has been pancreas islet transplantation, and so this is an area very close to my heart.
There's exciting things out there, and I can give you an example, but let me first say that we are going into the scientific review divisions.
proactively, something that's never been done before, and asking them, what are the most amazing treatments that you are seeing in the pipeline, even in the most early stage?
And we're asking our scientific reviewers, are you seeing any data that's promising, even animal studies, preclinical, phase one?
even something just based on a mechanism of action.
And if so, we don't want to be in a receive-only mode as an FDA.
We want to reach out to the company and see how we can facilitate, how we can partner.
We will not cut corners on our scientific review safety standards.
That review is impeccably independent, and it will always be independent.
Showing 181–200 of 939 · page 10 of 47
← Previous
Next →